ScholarIQanswers from OpenAlex & ORCID
Alice T. Shaw
ResearcherPublications, citations & collaboration network
Alice T. Shaw is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Alice T. Shaw have?
ScholarIQindexed works
Alice T. Shaw has 692 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Alice T. Shaw have?
ScholarIQcitation count
Alice T. Shaw has 73,400 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Alice T. Shaw?
ScholarIQh-index
Alice T. Shaw has an h-index of 116 in OpenAlex.
What is the i10-index of Alice T. Shaw?
ScholarIQi10-index
Alice T. Shaw has an i10-index of 290 in OpenAlex.
What is the ORCID of Alice T. Shaw?
ScholarIQorcid
The ORCID for Alice T. Shaw is on the source record.
What is the OpenAlex record for Alice T. Shaw?
ScholarIQopenalex
The OpenAlex for Alice T. Shaw is on the source record.
What are the most-cited papers on Alice T. Shaw?
ScholarIQmost cited works
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo‐Jack, Alice T. Shaw
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata, Subba R. Digumarthy, Alexa B. Turke, Panos Fidias, Kristin Bergethon, Alice T. Shaw, Scott Gettinger, Arjola K. Cosper, Sara Akhavanfard, Rebecca S. Heist, Jennifer S. Temel, James G. Christensen, John C. Wain, Thomas J. Lynch, Kathy Vernovsky, Eugene J. Mark, Michael Lanuti, A. John Iafrate, Mari Mino–Kenudson, Jeffrey A. Engelman
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok